Innocoll CEO and leadership

Gwendolyn Niebler is a CMO at Innocoll Holdings.

Mark Uhle is a Vice President and Chief Financial Officer at Innocoll Holdings and is based in Landenberg, Pennsylvania. He has worked as Vice President, Internal Audit Services at AstraZeneca; Management Trainee/Assistant Loan Officer at Special Loans; and CFO IPR Pharmaceuticals at AstraZeneca. Mark studied at The Wharton School between 1990 and 1992 and Northwestern University between 1982 and 1986.

Pharmaceutical Senior Executive with executive leadership experience with a small specialty biotech company, two industry leaders and an entrepreneurial biotech startups. Demonstrated ability to lead organizations to reach aggressive multi-billion dollar annual goals in challenging environments. Commercialization expertise from early product design, brand launches to growth throughout a brand's lifecycle of specialty and primary care medicines. Business development success including favorable outcomes with licensing and leading partnerships. Experience to lead as well as expertise to execute and achieve.

Rich Fante is a Board Member at Inhibikase Therapeutics Inc, Board Member at Natl Pharmaceutical Council, and Pres:US Bus/VP:Americas at AstraZeneca and is based in Newtown Square, Pennsylvania. He has worked as Chief Executive Officer at Innocoll Holdings, Board Member at Innocoll Holdings, and Chairman at Natl Pharmaceutical Council. Richard attended University of North Carolina at Chapel Hill between 1990 and 1991 and Princeton University between 1984 and 1987.